<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993742</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20190163H</org_study_id>
    <nct_id>NCT04993742</nct_id>
  </id_info>
  <brief_title>Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes</brief_title>
  <acronym>MOMSPlacenta</acronym>
  <official_title>Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes (MOMS Placenta)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Incarnate Word</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>59th Medical Wing</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the Incarnate Word</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the associations of prenatal maternal anxiety to placental histologic findings, and&#xD;
      the pro-inflammatory, anti-inflammatory, and immunoregulatory cells found in the placenta and&#xD;
      determine the effect of maternal anxiety on the association between placental molecular&#xD;
      changes on pregnancy and birth and infant outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: Explore the associations of prenatal maternal anxiety to placental histologic&#xD;
      findings, and the pro-inflammatory, anti-inflammatory, and immunoregulatory cells found in&#xD;
      the placenta and determine the effect of maternal anxiety on the association between&#xD;
      placental molecular changes on pregnancy and birth and infant outcomes.&#xD;
&#xD;
      Subject Population: Prenatal patients receiving obstetrical care at the San Antonio Military&#xD;
      Medical Center will be the focused population. Patients must be 18 years or older and&#xD;
      planning to deliver at the San Antonio Military Medical Center.&#xD;
&#xD;
      Design: The study is a repeated measures longitudinal design in which patients will complete&#xD;
      psychosocial measures of prenatal anxiety, depression, and resilience at multiple data points&#xD;
      during their pregnancies (at 12, 16, 24, and 32 weeks gestation). Placental tissue collected&#xD;
      after birth will be used to obtain histologic, microscopic, and molecular data. Pregnancy and&#xD;
      neonoatal outcome data including gestational age at delivery, infant birthweight, mode of&#xD;
      delivery, and pregnancy complications, including pre-eclampsia, gestational hypertension,&#xD;
      gestational diabetes, and perinatal and neonatal infections will be collected from the&#xD;
      maternal and infant medical records.&#xD;
&#xD;
      Procedures: Participants will complete multiple psychosocial measures at 12, 16, 24, and 32&#xD;
      weeks gestation. Placental tissue will be collected at delivery, gross and microscopic&#xD;
      examinations will occur for all placentas of women consented to the study. Histopathological&#xD;
      findings will be classified according to standard guidelines and coded into categories that&#xD;
      identify vascular malperfusion or uteroplacental vascular insufficiency and maternal&#xD;
      inflammatory disorders. Tissue biopsies will be frozen and maintained until they can be batch&#xD;
      run. Each biopsy will be homogenized and divided into groups for analysis for RNA expression,&#xD;
      protein expression, hormonal and oxidative stress biomarkers. Linear mixed models will be&#xD;
      used for all normally distributed continuous data. Binary or dichotomized outcomes will be&#xD;
      assessed through mixed model logistic regression. Measurement times, adjusting for age,&#xD;
      employment status, prior deliveries, marital status, education, deployment of partner, and&#xD;
      MOMS group will be included within the models. Each prenatal variable, anxiety, self-esteem,&#xD;
      depression, and resilience will be longitudinally regressed on measurement time to obtain&#xD;
      slopes through best linear unbiased predictor. The results slopes will be used to determine&#xD;
      any significant effects for prenatal psychosocial scores to pregnancy complications, birth&#xD;
      and infant outcomes, and to the physiologic data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a repeated measures, longitudinal design</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Coded histopathology slides will be sent to pathologist for evaluation with only a study number</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the correlations between prenatal maternal anxiety to placental histological findings</measure>
    <time_frame>at time of delivery</time_frame>
    <description>Correlate % of participants with high incidences of pregnancy related anxiety measured by the MOMS questionnaire to histological assessment of placenta tissue biopsies measuring Th1, Th2, Oxidative Stress hormones, &amp; RT-PCR for RNA expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Explore the correlations between prenatal maternal anxiety and the function of pro-inflammatory, anti-inflammatory, and immunoregulatory cells found in placental tissue.</measure>
    <time_frame>at time of placenta collection</time_frame>
    <description>Correlate % of participants with high incidences of pregnancy related maternal anxiety measured by the MOMS questionnaire to histological assessment of placenta tissue biopsies measuring oxidative stress hormone biomarkers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the effect of maternal anxiety on between placental molecular changes on pregnancy and birth and infant outcomes.</measure>
    <time_frame>Through study completion and average of 1 year</time_frame>
    <description>Correlate% of participants with high maternal anxiety on birth outcomes which will be assessed using MOMS post-partum psychosocial questionnaire, collecting birth and infant delivery outcomes such as birth wt, delivery complications, antenatal history, &amp; infant complications. Placenta tissue will be analyzed through punch tissue biopsies for immunological, inflammatory and hormonal changes examining gross placental features, vascular malperfusion or insufficiency, and maternal inflammatory disorders.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Placental Dysfunction</condition>
  <condition>Prenatal Stress</condition>
  <arm_group>
    <arm_group_label>MOMS Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.&#xD;
Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups&#xD;
No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MOMS Intervention</intervention_name>
    <description>Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.</description>
    <arm_group_label>MOMS Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Active Duty and DoD beneficiary gravid women,&#xD;
&#xD;
          -  18 years of age or older,&#xD;
&#xD;
          -  Receiving prenatal care at SAMMC,&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Military dependent daughters&#xD;
&#xD;
          -  VA beneficiaries&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Weis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Incarnate Word</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joint Base San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of the Incarnate Word</investigator_affiliation>
    <investigator_full_name>Karen L. Weis</investigator_full_name>
    <investigator_title>Professor, Brigadier General Lillian Dunlap Endowed Chair</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04993742/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04993742/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

